Articles tagged with Drug Studies
Researchers have successfully lowered levels of mutant huntingtin protein in patients with Huntington disease, making the treatment safe and well-tolerated. The trial enrolled 46 patients and found significant decreases in disease-causing protein levels without serious adverse reactions.
A new study demonstrates the safety of a potential treatment for ischemia-reperfusion injury in human lung transplant patients, showing no dose-limiting toxicities or 30-day mortality. The treatment, Regadenoson, has the potential to improve survival rates and quality of life for lung transplant recipients.
A randomized, double-blind, placebo-controlled study found that eculizumab significantly reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder. Nearly 98% of patients treated with eculizumab had not relapsed after 48 weeks, compared to 63% for those on the placebo.
A new study investigates potential botanical-drug interactions (BDIs) with Boswellia serrata extract, a widely used anti-inflammatory supplement. The study compared two in vitro methods and found that the sandwich-cultured human hepatocyte model is a more accurate predictor of BDIs.
A new drug combination of gentamicin and azithromycin shows promising results in treating treatment-resistant gonorrhoea, with a cure rate of 91% compared to 98% for the current ceftriaxone treatment. The study suggests that gentamicin could be used as an alternative for patients who are allergic or intolerant to ceftriaxone.
Top doctor David Nutt and mother of Alfie Dingley Hannah Deacon argue that many children are still not getting the treatment they need. Despite a law change in 2018, access to medical cannabis remains slow due to lack of training, fear of prescribing off licence, and difficulties obtaining supplies.
A vaccine combining a fentanyl antigen with tetanus toxoid has been shown to reduce fentanyl choices and increase food choices in rats, with effects lasting several months. The findings suggest the vaccine may decrease dangerous drug-taking behavior and increase healthier behaviors.
A study found that poor sense of smell is associated with a 46% higher mortality rate at year 10 and 30% higher mortality rate at year 13 compared to those with good olfaction. The association could not be explained by demographic characteristics, lifestyle, or comorbid conditions.
A clinical trial found liraglutide, an existing adult diabetes medication, effectively treats Type 2 diabetes in children. The study showed a significant reduction in A1C levels and improvements in glycated hemoglobin levels, offering new treatment options for this age group.
A new SGLT2 inhibitor medication has been shown to significantly slow the progression of chronic kidney disease (CKD) in patients with diabetes. The CREDENCE trial demonstrated a 34% reduction in the risk of end-stage kidney disease, as well as improved cardiovascular outcomes.
Stroke survivors are at up to four times greater risk of osteoporosis, bone breaks, and falls. Despite this, less than one-third of older women in the US are screened for osteoporosis.
A roadside survey found that nearly one in seven drivers with children in the car tested positive for THC, highlighting the need for better roadside testing for THC. The study also showed that drivers with children were less likely to test positive for THC than those without children.
Researchers at Ruhr-University Bochum found that administering cortisol after exposure therapy does not reinforce positive outcomes in anxiety disorders. The study, which tested arachnophobics, showed that patients who received cortisol were more likely to relapse when encountering a spider in a different context.
Researchers discover that inhibiting neutrophils, a type of white blood cell, can prevent blood clots in patients with antiphospholipid syndrome. The study found that two drugs, CGS21680 and dipyridamole, reduced the formation of sticky structures called NETs that trigger blood clots.
A Phase II trial led by the University of Texas MD Anderson Cancer Center reports a 90% response rate for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp. The treatment was effective regardless of prior therapy, and survival rates were relatively high at 59% and 52% at 18 and 24 months, respe...
A clinical trial has shown that targeted therapy tagraxofusp is effective in treating blastic plasmacytoid dendritic-cell neoplasm (BPDCN), a rare and aggressive blood cancer. The therapy, which targets the CD123 protein, has been approved by the FDA for use in BPDCN patients.
Researchers have developed a blood test that can identify genetic faults in cancer patients' blood, enabling clinicians to select targeted treatment options. The study showed that 11 out of 100 patients were successfully matched with molecularly matched clinical trials.
A new experimental compound inhibits clot formation without raising the risk of bleeding, providing an effective and safer alternative to current therapies. The study found that the drug is well-tolerated at high doses and has a rapid, specific, and reversible action on platelets.
The Patient-Centered Outcomes Research Institute (PCORI) has approved $44.6 million to fund studies comparing the best ways to treat health conditions that impose high burdens on patients, caregivers, and the healthcare system. The newly approved awards focus on improving treatment for opioid use disorder (OUD), with a total of four aw...
A recent study by Georgetown University Medical Center found that only a quarter of PCORI-funded trials between 2015-2018 examined primary care, while specialty care received the majority funding. The study's authors argue that this is wasteful, as most healthcare is accessed within primary care settings.
Researchers developed a novel bioelectronic treatment that significantly reduces swelling and inflammation in rheumatoid arthritis patients. The non-invasive vagus nerve stimulation treatment inhibits the production of cytokines, proteins that mediate inflammation.
A study found that metformin reduces left ventricular hypertrophy (LVH) in prediabetic and pre-existing heart disease patients, leading to lower cardiovascular risks. The MET-REMODEL Trial showed significant benefits of metformin on LVH, blood pressure, oxidative stress, and body weight.
A landmark clinical trial shows that canagliflozin lowers the risk of kidney failure by 30% in people with Type 2 diabetes and kidney disease. The study also found a significant reduction in cardiovascular events, providing a promising new treatment option for patients at high risk.
Research finds increased indicators of despair, including depression and suicidal ideation, among Gen X-ers in their late 30s and early 40s, regardless of demographic group.
Researchers found a link between prostate medicines and increased risk of type 2 diabetes in men taking 5-alpha-reductase inhibitors. Men on these medications should be monitored for warning signs of diabetes and have their prescriptions adjusted if necessary.
Scientists discovered that providing rodents with more space, exercise and toys before a spinal cord injury can 'prime' their cells, making it more likely for damaged nerves to regenerate. Researchers also found a key molecule called CREB-Binding Protein (CBP) that may be effectively reprogramming nerve cells.
A new study published in Addiction found that medication treatment for opioid use disorder significantly reduces the risk of arrest and incarceration. The research, led by UMass Amherst public health scientist Elizabeth Evans, used data from a large randomized clinical trial to compare the effects of two medications on social outcomes.
Researchers have identified a common species of seaweed, Laminaria ochroleuca, as a rich source of bacteria with antimicrobial and anticancer activities. The study reveals that extracts from these Actinobacteria inhibited growth of various pathogens and showed selective anticancer activity.
A study by ISGlobal identifies West African regions where treating livestock with ivermectin can significantly impact malaria transmission. The analysis highlights the potential of this strategy to reduce malaria prevalence among children under 10 years of age and improve community health.
A meta-analysis of international studies found that anti-inflammatory medicine can have a beneficial effect on symptoms of depression. Six different medications showed an antidepressant effect, and the results were present when compared to a placebo in patients with physical diseases and depressive symptoms.
A study found that heart failure patients are more likely to use the medication ivabradine when it is prescribed before hospital discharge. This can lead to a reduction in heart rate and improved outcomes. However, adoption of the therapy has been slow due to high cost and provider lack of familiarity.
Researchers at McGill University tested the effectiveness of naproxen, a common NSAID, in preventing Alzheimer's disease. The two-year trial found no evidence that the medication slowed disease progression or reduced cognitive decline in people with a strong family history of AD.
A small NIH clinical trial found benralizumab, a FDA-approved asthma medication, improves HES symptoms with low side effects. The study showed significant reduction in eosinophils and HES-related symptoms, allowing some participants to taper off other therapies.
Researchers at the University of Pennsylvania have developed a targeted drug gilteritinib that helps patients with relapsed or refractory acute myeloid leukemia live longer. The trial showed significant survival benefits and well-tolerated side effects, offering a new treatment option for high-risk patients.
Adding savolitinib to osimertinib yields clinical responses in patients with EGFR-mutant non-small cell lung cancer and MET-driven acquired resistance. The combination therapy demonstrates efficacy in a patient population for whom chemotherapy is the current primary treatment option.
The first total-body PET/CT scanner has shown promising results in enhancing image quality, reducing scan time, and lowering dose. Clinical trials have demonstrated improved diagnostic capabilities with minimal impact on patient exposure.
A team of researchers has identified a 'druggable' mechanism for pathological tau protein aggregation, which could lead to new treatment options for devastating neurodegenerative diseases. The discovery focuses on the RASD2 gene and its potential as a target for farnesyl transferase inhibitors.
A new computer-based model developed by Johns Hopkins researchers accurately predicts which patients with a rare heart condition will benefit from an implanted defibrillator. The model identifies patients most likely to benefit from the device while preventing unnecessary surgery, potentially saving thousands of lives annually.
Researchers at the University of Utah Health found that pairing music with pain medications improved analgesic outcomes by up to 90% in mouse models. The study showed significant reductions in inflammation and pain responses, suggesting a potential therapeutic strategy for managing pain.
A collaborative project between C-Path and Japan's PMDA aims to generate critical data for safety decisions in early-stage clinical trials. The study will compare biomarkers in healthy Japanese volunteers with similar Western subjects, informing regulatory submissions.
A study found that patients with type 2 diabetes who are untreated develop signs of Alzheimer's disease 1.6 times faster than those without diabetes. Medication for diabetes may be keeping Alzheimer's away.
A new clinical trial found that burosumab significantly improves rickets and related outcomes in children with X-linked hypophosphatemia compared to conventional therapy. The study, which included 61 children, showed substantial healing of rickets in 72% of participants who received burosumab.
A study found that patients who stayed on phentermine longer experienced greater weight loss than those who took the drug for three months or less. Longer-term use was not associated with increased risk of heart attack, stroke, or death.
A clinical trial assessing the safety of experimental compound ANS-6637 has begun in healthy adults at the National Institutes of Health Clinical Center. The trial will evaluate how the compound affects opioid use disorder and provide groundwork for future studies to develop effective treatments for cravings, a major barrier to sobriety.
A big data study has identified certain ADHD medications that increase the risk of psychosis in young people. The research found that patients taking amphetamines are more likely to develop psychosis than those taking methylphenidates.
A study published in Alimentary Pharmacology & Therapeutics found that older patients with Crohn's disease can be safely treated with combined immunosuppression. The research showed that remission rates were similar between older and younger patients, and there was no increase in side effects in older patients.
Researchers found that Asian subgroups have varying risks of death from heart disease and stroke, with women losing more years due to stroke. The study identified unique risks for each subgroup, including cerebrovascular disease affecting Vietnamese and Filipino men and women, resulting in lost life expectancy.
A new Australian drug trial has achieved a remarkable result, clearing the bone marrow of leukemia in almost 60% of patients. The combination therapy, combining venetoclax with LDAC, led to a 54% response rate and half the study population surviving longer than 10 months.
A new trial found TAVR to be equal to or better than open-heart surgery for patients with severe aortic stenosis who are considered low surgical risk. The study showed that TAVR was associated with lower rates of disabling stroke and death from any cause, as well as improved quality of life and hemodynamics.
A one-off operation targeting kidney nerves successfully maintains reduced blood pressure in hypertension patients, with fewer medication requirements. The procedure, known as renal denervation, was found to be effective in controlling blood pressure without long-term safety concerns.
Patients who stopped taking aspirin three months after receiving a stent had a significantly lower rate of bleeding and no higher rate of death from any cause, heart attack, or stroke compared to those following standard therapy. The study's results balance ischemic and bleeding risks in patients undergoing PCI.
Researchers found that ticagrelor has comparable efficacy to clopidogrel in patients treated with clot busters for a heart attack. The trial also showed that ticagrelor is safe for use in this patient population, with low rates of major bleeding.
A recent study found that both radial and femoral approaches for percutaneous coronary intervention (PCI) are equally effective in terms of survival rates at 30 days. The research, which enrolled nearly 2,300 patients, suggests that operators can achieve similar results with either approach if they have efficient systems and teams in p...
Patients who stopped taking aspirin and continued clopidogrel fared significantly better after one year, with a reduced risk of bleeding and no increase in clot-related events. The study suggests that stopping DAPT after one month may be a good option for patients after drug-eluting stent implantation.
A large randomized controlled trial found that two frontline two-drug combinations including amlodipine significantly reduced blood pressure levels more than a third combination without amlodipine. The study, conducted in sub-Saharan Africa, showed that nearly half of adults have high blood pressure, often receiving ineffective treatment.
Researchers at Kazan Federal University have developed a two-gene medication that recovers motor functions in rats after spinal cord injuries. The medication, which targets VEGF and FGF2 genes, stimulates axon growth and regeneration by increasing blood flow and neuron survivability.
Transcatheter aortic valve replacement (TAVR) significantly reduces the primary endpoint of death, stroke, and re-hospitalizations in patients with severe, symptomatic aortic stenosis at low surgical risk. TAVR also shows lower rates of mortality, stroke, and repeat hospitalizations compared to surgery.
Researchers found that systematic depression screening after a heart attack did not impact patients' quality of life. Depression was identified in about 7% of screened patients, and interventions such as medication, phone-based psychotherapy sessions, or a combination both were shown to be effective in reducing depressive symptoms.
A new study found that taking statins reduces the risk of a second major adverse cardiovascular event by almost 50% when patients adhere to their prescribed regimen. However, only about six percent of patients in an insured population follow their statin medication as directed.
A recent study using big data analysis has found that catheter ablation is associated with a lower risk of stroke, death, and major bleeding in patients with atrial fibrillation. The research, led by Mayo Clinic, used a large cohort of patients to replicate the results of a clinical trial and provide complementary evidence for clinicians.